دورية أكاديمية
209P Trastuzumab plus lapatinib or chemotherapy in patients with HER2-positive advanced breast cancer refractory to anti-HER2 therapies: A randomized, multicenter, phase II trial (GIM12-TYPHER)
| العنوان: | 209P Trastuzumab plus lapatinib or chemotherapy in patients with HER2-positive advanced breast cancer refractory to anti-HER2 therapies: A randomized, multicenter, phase II trial (GIM12-TYPHER) |
|---|---|
| المؤلفون: | De Angelis, C., Pagliuca, M., Gamucci, T., Mansutti, M., Ballatore, Z., De Laurentiis, M., Bordonaro, R., Pazzola, A., Leonardi, V., Bruzzese, D., Mosconi, A.M., Molica, C., Cinieri, S., Fabi, A., Del Mastro, L., Puglisi, F., de Placido, S., Giuliano, M., Arpino, G. |
| المصدر: | ESMO Open ; volume 8, issue 1, page 101398 ; ISSN 2059-7029 |
| بيانات النشر: | Elsevier BV |
| سنة النشر: | 2023 |
| المجموعة: | ScienceDirect (Elsevier - Open Access Articles via Crossref) |
| مصطلحات موضوعية: | Cancer Research, Oncology |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1016/j.esmoop.2023.101398 |
| الإتاحة: | https://doi.org/10.1016/j.esmoop.2023.101398Test https://api.elsevier.com/content/article/PII:S2059702923006245?httpAccept=text/xmlTest https://api.elsevier.com/content/article/PII:S2059702923006245?httpAccept=text/plainTest |
| حقوق: | https://www.elsevier.com/tdm/userlicense/1.0Test/ ; http://creativecommons.org/licenses/by-nc-nd/4.0Test/ |
| رقم الانضمام: | edsbas.9E0809A7 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.esmoop.2023.101398 |
|---|